Berlin Heart Inc. Receives FDA Orphan Product Development Grant



    THE WOODLANDS, TX, June 17 /CNW/ - Berlin Heart Inc. today announced it
has been awarded an Orphan Product Development Grant by the FDA, to support
the ongoing Investigational Device Exemption (IDE) study of the EXCOR(R)
Pediatric Ventricular Assist Device (VAD). Dr. Christopher Almond of the
Children's Hospital of Boston, and Bob Kroslowitz, Vice President of Clinical
Affairs for Berlin Heart Inc. will serve as Co-Principal Investigators for the
grant project "Safety and Efficacy of the Berlin Heart EXCOR Pediatric VAD as
a Bridge to Heart Transplantation."
    The Berlin Heart EXCOR Pediatric VAD is a system for mechanical support
of the heart in end-stage heart failure patients. It has been specifically
designed for use in pediatric patients of all age groups ranging from newborns
to teenagers. The device received unconditional approval for investigational
use in pediatric patients in the US in October 2008 and is currently
undergoing an IDE trial.
    The goal of the Office of Orphan Products Development Grant Program is to
encourage clinical development of products for use in rare diseases or
conditions. At this time, only clinical studies qualify for consideration. All
studies must be conducted under an Investigational New Drug (IND) application
or an Investigational Device Exemption (IDE). The grant awarded to Berlin
Heart provides three years of support.
    The number of grant awards varies each year depending on the availability
of funds. On-going studies are funded first with the remainder of funds going
to new studies. In recent years, the Office of Orphan Products Development
Grant Program has funded approximately twelve to fifteen new awards annually.
    Johannes Mueller, M.D., the CEO of Berlin Heart comments, "We are very
pleased we have been awarded this considerable grant for our ongoing EXCOR
Pediatric IDE study. We see the awarded grant as a clear indicator for the
importance of our product and for the potential it has to make a life-saving
difference for pediatric patients."

    About EXCOR(R) Pediatric

    The EXCOR Pediatric Ventricular Assist Device is a mechanical cardiac
support system for critically ill pediatric patients suffering from severe
heart failure. EXCOR Pediatric has been used in more than 500 pediatric
patients worldwide ranging from newborns with 2.2 kg body weight to teenagers.
EXCOR is currently under clinical investigation for pediatric patients in USA.

    About Berlin Heart

    Berlin Heart GmbH is the only company worldwide that develops, produces,
and distributes implantable and external ventricular assist devices (also
called mechanical heart support systems) for patients of every age and body
size. The company is market leader in Germany and Europe.
    The company also manufactures the implantable left ventricular assist
device INCOR(R), which has been designed for long-term application in adult
patients. The longest the device has supported a patient so far is more than
five and a half years and ongoing. INCOR is not FDA approved, but widely used
in Europe.





For further information:

For further information: Linda Buerk, Manager Marketing & PR, Phone:
+49(0)30-8187-2650, Mobile: +49(0)173-629-0803, buerk@berlinheart.de

Organization Profile

BERLIN HEART GMBH

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890